---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-046574"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:44:00.944305+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroGen CMO Mark Eisner resigns; search underway for replacement

## Summary
- CMO Mark Eisner resigns effective Sept 8, 2023; departure voluntary with no disagreement.
- Eisner to serve as consultant through Oct 11, 2023 at $15K/month; equity awards continue vesting.
- Company has initiated search for a new Chief Medical Officer.

## SEC filing metadata
- accession: 0000950170-23-046574
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023046574/0000950170-23-046574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023046574/fgen-20230831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-046574
- JSON: https://secwatch.observer/filing/0000950170-23-046574.json
- Plain text: https://secwatch.observer/filing/0000950170-23-046574.txt

## Key facts
- Executive change
  Mark Eisner resigned as Chief Medical Officer at KYNTRA BIO, INC..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc. (the "Company"), effective September 8, 2023, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023046574/0000950170-23-046574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.